China’s Sinovac Biotech Ltd yesterday began a late-stage human trial that would involve as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate, which it is developing with Indonesian state-owned peer Bio Farma.
Separately on Monday, Sinovac released details from a mid-stage, or Phase 2, study in which it said the vaccine candidate appeared to be safe and induced detectable antibody-based immune responses in subjects.
CORONAVAC
Photo: Reuters
The vaccine candidate, known as CoronaVac, is among a few potential vaccines that have entered late-stage trials for a large-scale study to gather proof of efficacy for regulatory approval.
CoronaVac is already undergoing a late-stage trial in Brazil and Sinovac expects to also test it in Bangladesh.
Sinovac’s Indonesia trial comes as Southeast Asia’s most populous country grapples with spiking infection numbers, with more than 127,000 cases recorded as of yesterday. The trial has so far recruited 1,215 people and would last six months.
“The threat of COVID-19 will not subside until a vaccine is given to all the people,” Indonesian President Joko Widodo said at a ceremony to begin the trial in Bandung, West Java. “Hopefully in January, we can produce and vaccinate everyone in the country.”
In addition to Bio Farma and Sinovac, private Indonesian firm Kalbe Farma and South Korea’s Genexine are cooperating to produce a separate vaccine. It is yet unclear how many doses these partnerships will produce and by when.
FEVER RATE
In Sinovac’s mid-stage trial involving 600 participants in China, the rate of fever in patients was lower than other COVID-19 candidates, including one from AstraZeneca, the study showed ahead of peer review.
Mid-stage trials usually test a candidate’s safety and ability to trigger an immune response in a relatively small number of people before it enters late-stage tests.
The study noted that the process to make the vaccines used in the Phase 2 trial was more optimized than in Phase 1, which produced more immunogens and triggered better immune responses.
Vaccines used in the late-stage trials would be made using the optimized process, a Sinovac spokesman said.
The Phase 2 results only included antibody-based immunity, the researchers said, adding that the candidate was being evaluated for other important components of the immune system.
Sinovac is testing its vaccine abroad because China is no longer a satisfactory site for late-stage trials due to the low number of new infection cases.
An American scientist convicted of lying to US authorities about payments from China while he was at Harvard University has rebuilt his research lab in Shenzhen, China, to pursue technology the Chinese government has identified as a national priority: embedding electronics into the human brain. Charles Lieber, 67, is among the world’s leading researchers in brain-computer interfaces. The technology has shown promise in treating conditions such as amyotrophic lateral sclerosis and restoring movement in paralyzed people. It also has potential military applications: Scientists at the Chinese People’s Liberation Army have investigated brain interfaces as a way to engineer super soldiers by boosting
Indonesian police have arrested 13 people after shocking images of alleged abuse against small children at a daycare center went viral, sparking outrage across the nation, officials said on Monday. Police on Friday last week raided Little Aresha, a daycare center in Yogyakarta on Java island, following a report from a former employee. CCTV footage circulating on social media showed children, most younger than two, lying on the floor wearing only diapers, their hands and feet bound with rags. The police have confirmed that the footage is authentic. Police said they also found 20 children crammed into a room just 3m by 3m. “So
From post offices and parks to stations and even the summit of Mount Fuji, Japan’s vending machines are ubiquitous, but with the rapid pace of inflation cooling demand for their drinks, operators are being forced to rethink the business. Last month beverage giant DyDo Group Holdings announced it would remove about 20,000 vending machines — about 7 percent of their stock nationwide — by January next year, to “reconstruct a profitable network.” Pokka Sapporo Food & Beverage, based in Nagoya, also said last month it would sell its 40,000-machine operation to Osaka-based Lifedrink Co. “The strength of the vending machine
A highway bomb attack in a restive region of southwestern Colombia on Saturday killed 14 people and injured at least 38, the latest spate of violence ahead of next month’s presidential election. Authorities blamed the attack in the Cauca department — a conflict-ridden, coca-growing region — on dissidents of the now-disbanded FARC guerrilla army, who have been sowing violence across the country. “Those who carried out this attack ... are terrorists, fascists and drug traffickers,” Colombian President Gustavo Petro said on social media. “I want our very best soldiers to confront them,” he added. The leftist leader blamed the bombing
RSS